Jump to any asset
850 assets, updated daily
Boston Scientific vs Medtronic plc
VS
Comparative Analysis
MDT wins this head-to-head comparison due to its superior growth profile and stronger recent momentum, despite BSX trading closer to its 52-week low. MDT's higher revenue growth and more favorable analyst sentiment present a more compelling investment case at this juncture. While BSX shows a lower P/E ratio, its significant underperformance relative to its 52-week high and weaker technical indicators suggest a more challenging path forward. MDT's current price, while closer to its 52-week high, is supported by positive earnings surprises and a higher median analyst target, indicating greater upside potential. The dividend yield for MDT, though small, also offers a slight income advantage over BSX's zero yield. Investors seeking growth and positive price action should favor MDT, while those prioritizing significant value and a potential turnaround might consider BSX, albeit with higher risk. MDT's stronger revenue growth and positive earnings surprises give it an edge over BSX. BSX's price is currently trading significantly below its 52-week high, signaling considerable weakness, whereas MDT, while also below its high, exhibits better relative strength. The technical indicators for MDT are more constructive, suggesting a potential for recovery, while BSX's indicators point to continued downward pressure. Analyst sentiment also favors MDT, with a higher median target price and a more positive rating distribution.
Key Differentiator
MDT's superior revenue growth of 13.7% and more positive technical momentum, evidenced by its price trading above key moving averages and a positive MACD, differentiate it from BSX. BSX, while boasting higher profit margins, is mired in a significant downtrend, trading far below its 52-week high and exhibiting significantly oversold technical indicators. This divergence in growth trajectory and current market sentiment makes MDT the more attractive asset for immediate investment.
Joint Outlook
MDT is expected to maintain its positive momentum in the next 6-12 months, driven by its strong revenue growth and favorable analyst sentiment. Potential upside exists towards its median analyst target of $106, though it faces resistance near its 52-week high. A scenario where MDT continues to beat earnings expectations and expands its market share could see it challenge previous highs. BSX faces a more uncertain outlook; a recovery would likely require a significant turnaround in its technicals and a clear catalyst to drive earnings and revenue growth. If BSX fails to stabilize, it risks further declines, potentially testing its 52-week low. A positive scenario for BSX would involve a broader market rally lifting all boats or specific company news improving its fundamental outlook.
Price Analysis Comparison
Valuation Metrics
| Metric | BSX | MDT |
|---|---|---|
| P/E Ratio | 18.20 | 22.64 |
| Market Cap | 62.46B | 117.19B |
| Price/Sales | 3.10 | 3.13 |
| Price/Book | 2.61 | 2.38 |
| EV/EBITDA | 13.57 | 13.27 |
| Dividend Yield | N/A | N/A |
MDT trades at a higher P/E ratio of 22.64 compared to BSX's 18.20, suggesting MDT is valued more richly by the market. However, BSX is trading at $42.91, which is only 1.77% above its 52-week low of $42.20, indicating significant distress or a potential value trap. In contrast, MDT is trading at $90.56, which is 23.54% above its 52-week low of $73.31, showing more resilience and a healthier trading range. BSX's price is a substantial 59.39% below its 52-week high of $105.72, while MDT is 14.82% below its 52-week high of $106.33. This suggests BSX has a longer way to recover to reach prior highs, whereas MDT's downside appears more limited from its peak.
Profitability & Efficiency
| Metric | BSX | MDT |
|---|---|---|
| Rev. Growth (Qtly) | 7.50% | 13.70% |
| Profit Margin | 17.50% | 13.93% |
| Return on Equity | 15.34% | 10.65% |
| Return on Assets | 6.19% | 5.12% |
| Debt/Equity | 50.15 | 55.37 |
BSX exhibits a superior net profit margin of 17.5% compared to MDT's 13.93%. Furthermore, BSX demonstrates a higher return on equity at 15.34% versus MDT's 10.65%. Despite BSX's higher margins and ROE, MDT's stronger revenue growth and market position may offer better long-term profitability potential, especially if it can improve its margin efficiency.
Earnings Reality Check
BSX
Last 5 Qs: BSX beat estimates 4x out of 5. Fell 2x after beats. (Sell the news?)
MDT
Last 4 Qs: MDT beat estimates 4x out of 4. Fell 2x after beats. (Sell the news?)
Technical Indicators
| Indicator | BSX | MDT |
|---|---|---|
| RSI (14) | 24.63 | 40.11 |
| 50-Day MA | $46.94 | $87.68 |
| 200-Day MA | $65.69 | $89.54 |
MDT shows a more constructive technical picture, with its price at $90.56 trading above both its 50-day ($87.68) and 200-day ($89.54) moving averages, indicating a short-to-medium term uptrend. Its RSI of 40.11 suggests room for upward movement before becoming overbought. BSX, conversely, is trading at $42.91, significantly below its 50-day ($46.94) and 200-day ($65.69) moving averages, signaling a strong downtrend. BSX's RSI is significantly oversold at 24.63, and its Stochastic is also extremely low at 1.71, pointing to persistent selling pressure. MDT's MACD is positive at 1.13, while BSX's MACD is negative at -1.07, further reinforcing MDT's bullish momentum.
AI Analyst Sentiment
Technical rating — based on current price action versus moving averages and momentum. This measures short-term chart trend, not analyst opinion or company fundamentals.
BSX
Technical Score: 21/100
MDT
Technical Score: 70/100
Why the ratings differ: BSX currently scores poorly on technical momentum (price sitting below key moving averages), while the analyst view below reflects forward-looking estimates of the business. A stock can be technically weak and still carry bullish analyst targets: the two measure different things over different horizons.
Analyst sentiment strongly favors MDT, with a median target price of $106, representing a 17.05% upside from its current price of $90.56. The analyst ratings for MDT are predominantly 'Buy' (17) and 'Strong Buy' (3). BSX has a median analyst target of $60, indicating a 39.83% potential upside from its current price of $42.91, but this is coupled with a more mixed rating distribution including 5 'Hold' ratings alongside 8 'Strong Buy' and 18 'Buy' ratings. The higher median target and more concentrated 'Buy' ratings for MDT suggest greater conviction from analysts.Risk Stratification
| Metric | BSX | MDT |
|---|---|---|
| Beta (Volatility) | 0.57 | 0.57 |
| Sharpe Ratio | -0.85 | 0.24 |
For MDT, the primary risks include its higher valuation multiples compared to BSX, which could lead to a sharper correction if growth expectations are not met. Competition within its sector and potential regulatory changes could also impact its market position and profitability. Furthermore, its reliance on continued revenue growth presents a risk if market demand softens. BSX faces significant risks related to its current downtrend and significantly oversold technicals, suggesting potential for further price declines. Its lower profitability metrics and the large gap between its current price and 52-week high indicate underlying business challenges or market concerns that need to be addressed. A failure to reverse its current negative momentum could lead to prolonged underperformance.
Comparative ProTips
- Consider MDT for its stronger growth and positive technical momentum, aligning with current market trends.
- BSX's significant oversold condition presents a high-risk, high-reward turnaround position; monitor for signs of stabilization before considering.
- The significant difference in revenue growth rates (MDT at 13.7% vs BSX at 7.5%) is a key factor favoring MDT's long-term prospects.
Monte Carlo Projection (10yr)
Actionable Trade Plans
Compare entry, exit, and risk management levels for both assets
Select Your Trade Bias
Risk Tolerance
Conservative
3%
Aggressive
Portfolio Value
$
✎
Position Size: $200 - $300 per asset
BSX
Current: $42.91
ENTRY ZONES
Conservative
$40.76
Aggressive
$42.91
RISK MANAGEMENT
STOP LOSS
$39.54
MAX LOSS
-3%
Volatility-Adjusted Stop Loss
Calculated based on volatility and technical support levels.
Profit Targets (Based on Conservative)
+5%
$42.80
+10%
$44.84
+15%
$46.88
MDT
Current: $90.56
ENTRY ZONES
Conservative
$86.03
Aggressive
$90.56
RISK MANAGEMENT
STOP LOSS
$83.45
MAX LOSS
-3%
Volatility-Adjusted Stop Loss
Calculated based on volatility and technical support levels.
Profit Targets (Based on Conservative)
+5%
$90.33
+10%
$94.64
+15%
$98.94
Calculate Your Trade
Disclaimer
This comparison involves assets with varying risk profiles. The content is for educational purposes only. Identifying the stronger asset is based on relative strength (RS) and technical convergence. Past correlation does not guarantee future lockstep movement. Trading involves risk of loss. Note: The AI favored MDT based on price momentum. This is valid for the specified timeframe only.
Frequently Asked Questions
Which stock is a better buy, BSX or MDT?+
MDT is the preferred buy due to its stronger revenue growth (13.7% vs 7.5%), more positive technical indicators, and higher median analyst target price ($106 vs $60). While BSX has higher profit margins, its significant price weakness and oversold technicals present higher risk.
What are the key risks for BSX and MDT?+
MDT's main risk is its higher valuation and reliance on continued growth. BSX faces significant risks from its current downtrend, oversold technicals, and the large gap between its price and 52-week high, suggesting potential for further declines.
How do BSX and MDT compare on valuation?+
MDT has a higher P/E ratio (22.64 vs 18.20), but BSX is trading much closer to its 52-week low and significantly further from its 52-week high, suggesting MDT's valuation is better supported by its current market position and momentum.
What is the earnings outlook for BSX and MDT?+
Both companies have positive earnings surprise records. MDT's recent earnings beat was accompanied by a positive price reaction and stronger revenue growth (13.7%), indicating a more favorable earnings outlook compared to BSX's 7.5% revenue growth and slight price dip on its latest beat.
How do the technical indicators compare for BSX and MDT?+
MDT's technicals are more bullish, with its price above key moving averages (SMA 50/200) and a positive MACD. BSX is in a strong downtrend, trading well below its moving averages with significantly oversold RSI and Stochastic indicators.
What is the analyst sentiment towards BSX and MDT?+
Analysts are more bullish on MDT, reflected in a higher median target price of $106 and a higher concentration of 'Buy' and 'Strong Buy' ratings. BSX has a lower median target of $60 and a more mixed rating distribution.